NextPharma's Growth Strategy Leadership has, "laid a path to become one of the leaders in the global pharmaceuticals contract manufacturing market."
NextPharma Technologies has been selected by Frost & Sullivan to receive its 2006 Growth Strategy Leadership Award for the European pharmaceutical contract manufacturing market.
While Europe's market for outsourced phamaceutical manufacturing services, comprising over 300 CMOs (contract manufacturing organisations), has increasingly relied on a rising tide of generic drugs for its 'bread and butter,' Asian countries offering services at a lower cost, have put European CMOs under severe pressure. In this competitive climate, the key to success lies in implementing a business model to build long-term strategic partnerships with customers by offering value and countering the shift of manufacturing.
NextPharma offers strategic 'end-to-end' state-of-the-art services extending from development, manufacturing and logistics, catering not only for generics companies, but also big pharma and biotechs. Margins increase when the supply chain is managed efficiently to reduce the number of players taking part in the product's life cycle.
NextPharma has effectively diversified its business to include a wider portfolio of customers within the healthcare sector of the life science industry rather than to focus on a select group. This has improved NextPharma's profitability through a twin-track approach of reducing the time to market while lowering the cost of product.
NextPharma operating eight manufacturing plants across Europe offers a broad range of services for cephalosporins, penicillin's, pellets, cytostatics, hormones, and conventional dosage formulations. Its presence in various countries provides NextPharma with the ability to cater for local markets as well as augment its capacity to supply into export markets.
NextPharma has been able to offer a broader range of services by acquiring key technologies and manufacturing plants from experienced contract manufacturing organizations. A key acquisition was UCB's Limay plant in France in September of 2004. This gave NextPharma expertise in liquid, sprays and suppositories, as well as a 5-year supply agreement.
NextPharma's agreement with Wyeth in January of 2005 to manufacture methotrexate, leveraging its expertise in lyophilization and parenteral manufacturing, is a clear pointer to the success of its growth strategy leadership.
Through its Growth Strategy Leadership, NextPharma has laid a path to become one of the leaders in the global pharmaceuticals contract manufacturing market.
About Frost & Sullivan and the Frost & Sullivan Awards.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years.
The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities.
Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
For more information, visit www.frost.com.
The Frost & Sullivan Best Practices Group performs research to identify best practices within each industry and functional discipline. The comprehensive analysis on best practices is an invaluable source to companies for new ideas to improve strategies and processes, which ultimately drive corporate growth. The research also identifies companies, products, processes and executives that have achieved world class performances. These achievements are recognized with Frost & Sullivan Best Practices Awards.
Further information about NextPharma:
See linked information about NextPharma
